Browse by category

Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether, obesity experts from King's College London and the Obesity Management Collaborative (OMC-UK) have warned. They stated that strict eligibility criteria means that only a small number of people will have access to the weight loss drug tirzepatide (Mounjaro) on the NHS, with those able to afford it paying privately for treatment. The researchers argue, in an edi